Koroner arter hastalığında SYNTAX skorunun yeri

Year 2018, Volume: 9 Issue: 4, 44 - 50, 25.12.2018

Ali Bağcı

https://doi.org/10.22312/sdusbed.476944

Cited By: 1

Abstract

Kardiyovasküler
hastalıklar ülkemizde ve gelişmiş ülkelerde mortalite ve morbiditenin en önemli
nedenidir. Kardiyovasküler hastalıklar arasında en yaygın olanı ise Koroner
Arter Hastalığı (KAH) olup yüksek mortalite ve morbidite ile ilişkilidir.  Koroner arter hastalığının %99’unda  etyolojik neden aterosklerozdur. Ateroskleroz
nedeniyle oluşan KAH ciddiyetini belirlemede altın standart yöntem koroner
anjiyografidir. Koroner anjiyografi hem tanı hem de tedavi yöntemidir. Bu
nedenle anjiyografi görüntülerine dayalı bazı skorlama sistemleri
geliştirilmiştir. SYNTAX skoru  (SYNergy
between PCI with TAXUS and Cardiac Surgery) koroner arter hastalığının anatomik
ciddiyetini  derecelendirmede kullanılan  skorlama sistemlerinden biridir. Bu derlemede
koroner arter hastalığında SYNTAX skoru kullanımının incelenmesi ve
literatürünün güncel bilgilerle özetlenmesi amaçlanmıştır.

Keywords

koroner arter hastalığı, koroner anjiyografi, SYNTAX skoru

References

• 1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. The lancet. 1997;349(9063):1436-42.
• 2. Sokolow MML, M. Cheitlin, MD. Coronary Heart Disease. In:Clinical Cardiology, A Lange Medical Book. 15th ed1990. 145-224 p.
• 3. Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219-27.
• 4. Napoli C, Glass CK, Witztum JL, Deutsch R, D'armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. The Lancet. 1999;354(9186):1234-41.
• 5. Tamminen M, Mottino G, Qiao J, Breslow J, Frank J. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arteriosclerosis, thrombosis, and vascular biology. 1999;19(4):847-53.
• 6. Williams KJ, Tabas I. The response‐to‐retention hypothesis of atherogenesis reinforced. Current opinion in lipidology. 1998;9(5):471-4.
• 7. Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. Bmj. 1995;311(7003):471-7.
• 8. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. New England Journal of Medicine. 1990;322(4):213-7.
• 9. Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European heart journal. 2013;34(38):2949-3003.
• 10. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama. 2001;285(19):2486.
• 11. Lee I-M, Rexrode KM, Cook NR, Manson JE, Buring JE. Physical activity and coronary heart disease in women: Is no pain, no gain passé? Jama. 2001;285(11):1447-54.
• 12. Yenigün M, Türker T, Ataoğlu HE, Temiz L, Ahbab S. From obesity to diabetes. Haseki Tıp Bülteni. 2005;43:1-12.
• 13. Hergenç G, Schulte H, Assmann G, von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis. 1999;145(1):147-56.
• 14. Gürbilek M, Gederet YT, Sökmen G. Diyabetik Olmayan Akut Koroner Sendromlarda Erken Dönem Yeni Bir Risk Önbelirleyicisi Olarak" Gelifl‹ nsülin Rezistans‹ ndeksi (G‹ R‹)’nin" De¤ erlendirilmesi. Anadolu Kardiyol Derg. 2002;3:194-201.
• 15. ONAT A, UYAREL H, HERGENÇ G, YAZICI M, UZUNLAR B, TÜRKMEN S, et al. Yüksek Riskli bir Örneklemimizde Lipoprotein (a): Dağılımı ve Bağıntıları Zemininde Türk Erkeklerinde İnsülinemi ile Ters İlişkisi Gözlemi. TÜRK KARDİYOLOJİ DERNEĞİ ARŞİVİ. 2004;32(2):82-90.
• 16. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Journal of the American College of Cardiology. 1999;34(4):1348-59.
• 17. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1, 2. Atherosclerosis. 1998;140(2):199-270.
• 18. Sucu M, Karadere A, Toprak N. Homosistein ve kardiyovasküler hastalıkları. Türk Kardiyol Dern Arş. 2001;29(3):181-90.
• 19. Onat A. Yazıcı M, Hergenç G, Doğan Y, Karabulut A, Sarı İ, ve ark. Popülasyona dayalı bir çalışmada lipoprotein (a): Klinik önemi kadınlarımızda daha mı fazla. Anadolu Kardiyol Derg. 2005;5:271-77.
• 20. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJL, Stampfer MJ, et al. Apolipoprotein (a) size and lipoprotein (a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clinical chemistry. 2004;50(8):1364-71.
• 21. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955-9.
• 22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England journal of medicine. 2002;347(20):1557-65.
• 23. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama. 2001;285(19):2481-5.
• 24. Amsterdam EA, Kirk JD, Bluemke DA, Diercks D, Farkouh ME, Garvey JL, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation. 2010;122(17):1756-76.
• 25. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2005;1(2):219-27.
• 26. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European heart journal. 2014;35(37):2541-619.
• 27. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51(4 Suppl):5-40.
• 28. Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van Es GA, et al. The ARTS study (Arterial Revascularization Therapies Study). Seminars in interventional cardiology : SIIC. 1999;4(4):209-19.
• 29. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, 3rd, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988;78(2):486-502.
• 30. Ijsselmuiden AJ, Ezechiels J, Westendorp IC, Tijssen JG, Kiemeneij F, Slagboom T, et al. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. American heart journal. 2004;148(3):467-74.
• 31. Hamburger JN, Serruys PW, Scabra-Gomes R, Simon R, Koolen JJ, Fleck E, et al. Recanalization of total coronary occlusions using a laser guidewire (the European TOTAL Surveillance Study). The American journal of cardiology. 1997;80(11):1419-23.
• 32. Crenshaw BS, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation. 2000;101(1):27-32.
• 33. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2018:ehy394-ehy.
• 34. Rencuzogullari I, Çağdaş M, Karakoyun S, Yesin M, Gürsoy MO, Artaç İ, et al. Propensity score matching analysis of the impact of Syntax score and Syntax score II on new onset atrial fibrillation development in patients with ST segment elevation myocardial infarction. Annals of Noninvasive Electrocardiology. 2018;23(2):e12504.
• 35. Ozturk D, Celik O, Erturk M, Kalkan AK, Uzun F, Akturk IF, et al. Utility of the logistic clinical syntax score in the prediction of contrast-induced nephropathy after primary percutaneous coronary intervention. Canadian Journal of Cardiology. 2016;32(2):240-6.
• 36. Kuyumcu MS, Kuyumcu A, Yayla Ç, Özbay MB, Ünal S, Açar B, et al. The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction. Acta Cardiologica Sinica. 2018;34(5):386.
• 37. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128(2):141-51.